Evidence map›Paper›PMID 34749633›Full record

ArticleBMC bioinformatics2021

Laniakea@ReCaS: exploring the potential of customisable Galaxy on-demand instances as a cloud-based service.

Marco Antonio Tangaro, Pietro Mandreoli, Matteo Chiara, Giacinto Donvito, Marica Antonacci, Antonio Parisi, Angelica Bianco, Angelo Romano, Daniela Manila Bianchi, Davide Cangelosi and 11 more

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. A Case of Food-Borne Salmonellosis in a Corn Snake (Animals : an open access journal from MDPI · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 1 country.

Marco Antonio Tangaro *Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Research Council (CNR), Via Giovanni Amendola 122/O, 70126, Bari, Italy.
Pietro Mandreoli *Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Research Council (CNR), Via Giovanni Amendola 122/O, 70126, Bari, Italy.
Matteo ChiaraInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Research Council (CNR), Via Giovanni Amendola 122/O, 70126, Bari, Italy.
Giacinto DonvitoNational Institute for Nuclear Physics (INFN), Section of Bari, Via Orabona 4, 70126, Bari, Italy.
Marica AntonacciNational Institute for Nuclear Physics (INFN), Section of Bari, Via Orabona 4, 70126, Bari, Italy.
Antonio ParisiIstituto Zooprofilattico Sperimentale Della Puglia e Della Basilicata, Via Manfredonia 20, 71121, Foggia, Italy.
Angelica BiancoIstituto Zooprofilattico Sperimentale Della Puglia e Della Basilicata, Via Manfredonia 20, 71121, Foggia, Italy.
Angelo RomanoNational Reference Laboratory for Coagulase-Positive Staphylococci Including Staphylococcus Aureus, Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10154, Turin, Italy.
Daniela Manila BianchiNational Reference Laboratory for Coagulase-Positive Staphylococci Including Staphylococcus Aureus, Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10154, Turin, Italy.
Davide CangelosiClinical Bioinformatics Unit, Scientific Direction, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy.
Paolo UvaClinical Bioinformatics Unit, Scientific Direction, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy.
Ivan MolinerisDepartment of Life Science and System Biology, University of Turin, Via Accademia Albertina, 13-1023, Turin, Italy.
Vladimir NosiDepartment of Computer Science, University of Turin, Via Pessinetto 12, 10049, Turin, Italy.
Raffaele A CalogeroDepartment of Molecular Biotechnology and Health Sciences, Via Nizza 52, 10126, Turin, Italy.
Luca AlessandriDepartment of Molecular Biotechnology and Health Sciences, Via Nizza 52, 10126, Turin, Italy.
Elena PedriniDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136, Bologna, Italy.
Marina MordentiDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136, Bologna, Italy.
Emanuele BonettiDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136, Bologna, Italy.
Luca SangiorgiDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136, Bologna, Italy.
Graziano PesoleInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Research Council (CNR), Via Giovanni Amendola 122/O, 70126, Bari, Italy. graziano.pesole@uniba.it.
Federico ZambelliInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Research Council (CNR), Via Giovanni Amendola 122/O, 70126, Bari, Italy. federico.zambelli@unimi.it.ORCID http://orcid.org/0000-0003-3487-4331
Istituto Ortopedico Rizzoli · ITIstituto Nazionale di Fisica Nucleare · ITUniversity of Milan · ITIstituto Giannina Gaslini · ITIstituto Zooprofilattico Sperimentale della Puglia e della Basilicata · ITIstituto Zooprofilattico Sperimentale del Piemonte Liguria e Valle d'Aosta · ITAccademia Albertina delle Belle Arti · ITInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies · ITUniversity of Turin · IT

Funding

Horizon 2020 Framework Programme 653549Horizon 2020 Framework Programme 824087Horizon 2020 Framework Programme 857650
6 · The paper itself

Abstract

backgroundImproving the availability and usability of data and analytical tools is a critical precondition for further advancing modern biological and biomedical research. For instance, one of the many ramifications of the COVID-19 global pandemic has been to make even more evident the importance of having bioinformatics tools and data readily actionable by researchers through convenient access points and supported by adequate IT infrastructures. One of the most successful efforts in improving the availability and usability of bioinformatics tools and data is represented by the Galaxy workflow manager and its thriving community. In 2020 we introduced Laniakea, a software platform conceived to streamline the configuration and deployment of "on-demand" Galaxy instances over the cloud. By facilitating the set-up and configuration of Galaxy web servers, Laniakea provides researchers with a powerful and highly customisable platform for executing complex bioinformatics analyses. The system can be accessed through a dedicated and user-friendly web interface that allows the Galaxy web server's initial configuration and deployment.

results"Laniakea@ReCaS", the first instance of a Laniakea-based service, is managed by ELIXIR-IT and was officially launched in February 2020, after about one year of development and testing that involved several users. Researchers can request access to Laniakea@ReCaS through an open-ended call for use-cases. Ten project proposals have been accepted since then, totalling 18 Galaxy on-demand virtual servers that employ ~ 100 CPUs, ~ 250 GB of RAM and ~ 5 TB of storage and serve several different communities and purposes. Herein, we present eight use cases demonstrating the versatility of the platform.

conclusionsDuring this first year of activity, the Laniakea-based service emerged as a flexible platform that facilitated the rapid development of bioinformatics tools, the efficient delivery of training activities, and the provision of public bioinformatics services in different settings, including food safety and clinical research. Laniakea@ReCaS provides a proof of concept of how enabling access to appropriate, reliable IT resources and ready-to-use bioinformatics tools can considerably streamline researchers' work.

Indexed as

Cloud ComputingCOVID-19Computational BiologyHumansSARS-CoV-2SoftwareBioinformaticsCloud computingCovid-19ELIXIRGalaxyLaniakeaNGSSARS-Cov-2Software environment

Identifiers

PMID34749633
PMCPMC8574934
OpenAlexW3214502395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.